Kane Biotech has signed a non-exclusive deal with Ottawa-based Ontario Medical Supply Inc. to distribute its revyve antimicrobial wound care products. The partnership aims to increase product availability across Canada by utilizing OMS's existing ties to provincial healthcare networks.
One of Only Two Authorized Distributors for Ontario Health atHome
The strategic value of this agreement lies in the unique market poistion of Ontario Medical Supply Inc. (OMS). According to the report, OMS is one of only two authorized distributors and price agreement holders for Ontario Health atHome, the provincial entity that manages publicly funded home and community care services. This status makes OMS a critical gatekeeper for any manufacturer seeking to enter the Ontario Health atHome formulary.
By partnering with OMS, Kane Biotech (TSX: KNE) gains a streamlined path to the home care sector. Under the terms of the arrangement, OMS will handle the purchasing, marketing, and support of the revyve Antimicrobial Wound Gel and Wound Gel Spray. In return, Kane Biotech will provide the necessary sales materials and approved product training to ensure the rollout is clinically sound .
Reaching 680,000 Patients and 11.1 Million Nursing Visits
The sheer scale of the target market underscores the potential of this distribution move. As reported, Ontario Health atHome serves more than 680,000 patients annually and recorded 11.1 million nursing visits during the 2024-25 period. For a company like Kane Biotech, these figures represent a massive clinical opportunity to deploy its products where the burden of acute and chronic wound care is most concentrated.
To support this volume, Ontario Medical Supply Inc. operates seven distribution centres across Ontario. This infrastructure allows OMS to provide reliable access to medical equipment and pharmaceuticals for emergency services, public-sector organizations, and individual healthcare professionals. This logistical footprint effectively solves the "last mile" problem for Kane Biotech's revyve line as it seeks to penetrate the Canadian community care market.
Combatting Biofilms and the Cost of Antibiotic Resistance
The revyve product line is designed to address a specific and costly clinical challenge: biofilms.. These layers of bacteria are primary contributors to antibiotic resistance in wounds, often leading to severe clinical outcomes and escalating healthcare expenditures. By targeting both biofilms and wound bacteria, Kane Biotech is positioning revyve as a tool to reduce the long-term financial and physical burden on the healthcare system.
The regulatory foundation for these products is already in place, which reduecs the risk for the distributor. The revyve Antimicrobial Wound Gel, Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser have all received U.S.. FDA 510(k) clearance. Furthermore, the wound gel and spray have specifically received Health Canada approval, ensuring they meet the stringent safety standards required for the Canadian market.
The Mystery of the Second Authorized Distributor
Despite the clarity regarding the scale of Ontario Health atHome, some critical details remain absent from the announcement. The report notes that OMS is one of two authorized distributors for the provincial body, yet it does not name the other entity. Understanding who the second distributor is would provide a clearer picture of the competitive landscape Kane Biotech is entering.
Additionally, while the agreement is descried as "non-exclusive," the specific financial terms and the duration of the contract were not disclosed. it remains unclear whether Kane Biotech intends to seek a similar partnership with the second authorized distributor to fully saturate the Ontario Health atHome network,or if the current arrangement with OMS is deemed sufficient for their immediate growth targets.
Comments 0